Patent intelligence · US
US 11891431
Removal of serine proteases by treatment with finely divided silicon dioxide
Removal of serine proteases by treatment with finely divided silicon dioxide
Patent details — US 11891431
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 6, 2024
- Expiration
- Feb 1, 2044
- Claims
- 19
- CPC classes
- A61K, A61K35/16, A61K38/1709, A61K39/39525
Quick answer
US 11891431 (Removal of serine proteases by treatment with finely divided silicon dioxide) is held by Takeda Pharm Limited ceutical Company Limited. Status: granted. Granted Feb 6, 2024. Expires Feb 1, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- 19
- CPC classes
- A61K, A61K35/16, A61K38/1709, A61K39/39525, A61K47/183, A61K9/0019
More from Takeda Pharm Limited ceutical Company Limited
Related pharmaceutical patents in our USPTO index.
-
US 12428403
N-(heterocyclyl and heterocyclylalkyl)-3-benzylpyridin-2-amine derivatives as SSTR4 agonists
granted -
US 12421188
Heterocyclic compound and use thereof
granted -
US 12419890
Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors
granted -
US 12415866
Monoclonal antibody inhibitor of Factor XIIa
granted -
US 12415782
Heterocyclic compound and use thereof
granted -
US 12409210
CNS delivery of therapeutic agents
granted -
US 12404237
Method of treating excessive sleepiness and/or cataplexy using n-{2-(([1,1′-biphenyl]-3-yl)methyl)pyrrolidin-3-yl}sulfonamide derivatives
granted -
US 12403154
Administration of sting agonist and checkpoint inhibitors
granted
Frequently asked questions
What is US patent 11891431?
US 11891431 (Removal of serine proteases by treatment with finely divided silicon dioxide) is held by Takeda Pharm Limited ceutical Company Limited. Status: granted. Granted Feb 6, 2024. Expires Feb 1, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11891431?
Takeda Pharm Limited ceutical Company Limited is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 1,436 pharmaceutical patents for this assignee.
When does US 11891431 expire?
Our index shows an expiration date of Feb 1, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.